20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 4-Dose Series in Healthy Infants

NCT04382326 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1997

Enrollment

INDUSTRY

Sponsor class

Conditions

Pneumococcal Disease

Interventions

BIOLOGICAL: 20-valent pneumococcal conjugate vaccine
BIOLOGICAL: 13-valent pneumococcal conjugate vaccine

Sponsor

Pfizer